Chr. Hansen reports solid organic growth of 9% in the first nine months of 2017/18

Chr. Hansen reports solid organic growth of 9% in the first nine months of 2017/18
Given the performance and cash-flow generation in the first nine months, an extraordinary dividend totaling EUR 105 million (DKK 5.94 per share) will be paid out on July 3, 2018.
Press Release | Jun 28. 2018 06:01 GMT

CEO Mauricio Graber: “We are pleased to report that we maintained the sales momentum in Q3"

Chr. Hansen reports solid organic revenue growth of 9% in the first nine months of 2017/18 (3% reported growth due to adverse currency impacts): Food Cultures & Enzymes 12%, Health & Nutrition 8% and Natural Colors 5%. EBIT before special items increased by 1% to EUR 219.9 million, corresponding to an EBIT margin before special items of 27.5%. In Q3, organic growth was 9%, and EBIT before special items increased by 3% to EUR 84.0 million, corresponding to an EBIT margin before special items of 29.7%.The outlook for 2017/18 is unchanged.

EUR million

Q3 2017/18 Q3 2016/17 Growth YTD 2017/18 YTD 2016/17 Growth
Revenue 282.7 278.4 2% 800.9 779.5 3%
EBIT before special items 84.0 81.6 3% 219.9 217.2 1%
Profit for the period 60.5 57.9 4% 158.1 155.8 1%
Free cash flow before acquisitions and special items 64.4 68.4 (6)% 75.4 98.3 (23)%
Organic growth, % 9% 10% 9% 10%
Gross margin, % 55.6% 54.2% 53.9% 53.8%
EBIT margin before special items, % 29.7% 29.3% 27.5% 27.9%
ROIC excl. goodwill, % 37.7% 39.2% 34.2% 37.4%


Pleased to report continued sales momentum
CEO Mauricio Graber says: “We are pleased to report that we maintained the sales momentum in Q3, led by broad-based growth in Food Cultures & Enzymes. In Health & Nutrition, the human health business in North America is improving, and growth in emerging markets remains strong. Animal health again delivered strong growth in EMEA, APAC and LATAM, where we are strengthening our presence. Growth in Natural Colors improved, driven primarily by APAC and EMEA.

Our strategic lighthouse projects – bioprotection, plant health, and human microbiome – all progressed well in the third quarter. Sales of bioprotective solutions grew approximately 25% in Q3, which was in line with expectations, bringing YTD organic sales growth to approximately 35%.

Plant health showed very strong sales growth, driven by the recently launched biological nematicides, Quartzo® and Presence®. We also extended the collaboration with FMC, our partner in plant health, and we look forward to launching our strong pipeline of new products in the years ahead.

In the human microbiome, we announced two significant scientific developments in Q3: A partnership with Prota Therapeutics to test our LGG® strain in a Phase III clinical trial to potentially develop a treatment for peanut allergy; and an exciting result from a Chr. Hansen-led clinical trial that demonstrated how ingesting a carefully selected probiotic strain can reduce certain side effects associated with the regular consumption of acetylicsalicylic acid – the active ingredient in aspirin.”

Given the performance and cash-flow generation in the first nine months, an extraordinary dividend totaling EUR 105 million (DKK 5.94 per share) will be paid out on July 3, 2018.

Outlook for 2017/18

The outlook for 2017/18 is unchanged from the announcement of April 11, 2018.


June 28, 2018 April 11, 2018
Organic revenue growth 8-10% 8-10%
EBIT margin before special items around 28.9% around 28.9%
Free cash flow before acquisitions, divestments and special items around EUR 188 million around 188 million


科 汉森是一家全球性且具备差异化的生物科技公司,为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森,我们拥有独特的优势,可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里,我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力,库存广泛且价值重大,包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外,我们还将挖掘释放有益菌的力量,以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司,我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动,公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。

分享